Differential apoptotic response in HPV-infected cancer cells of the uterine cervix after doxorubicin treatment.
This study aimed to evaluate differential apoptotic response in uterine cervical cancer cells with and without HPV infection after chemotherapy. CaSki (HPV 16-positive) and C33A (mutant p53 and HPV-negative) cells were used. Cell viability was assessed by trypan blue cell exclusion test. Apoptosis was evaluated by DNA fragmentation analysis and flow cytometric analysis. Differential apoptotic responses were evaluated using Western blot analysis after chemotherapy. Decreased cell viability and apoptosis were displayed in CaSki and C33A cells after chemotherapy using doxorubicin (DOX). Regarding apoptosis-related molecules, the appearance of cleaved PARP expression was more prominent in CaSki cells. p53 and p21 expression in CaSki cells were increased. On the other hand, JNK expression was different in C33A cells (increased) and CaSki cells (decreased). CaSki cells and C33A cells showed differential apoptotic responses after chemotherapy using DOX. CaSki cells seem to be related with p53/p21 expression, but C33A cells seem to be related with PARP-JNK expression, which is involved in the mitochondrial pathway.
Suh
Dong Soo
DS
Department of Obstetrics and Gynecology, Medical Research Institute, Pusan National University, Gyeongsangnam-do 626-770, Republic of Korea.
Kim
Seung Chul
SC
An
Won Geun
WG
Lee
Chang Hun
CH
Choi
Kyung Un
KU
Song
Jin Mi
JM
Jung
Jin Seup
JS
Lee
Kyu Sup
KS
Yoon
Man Soo
MS
D000903:Antibiotics, Antineoplastic / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects*; D002453:Cell Cycle; D045744:Cell Line, Tumor; D002470:Cell Survival; D053938:DNA Fragmentation; D004317:Doxorubicin / Q000494:pharmacology*; D005260:Female; D006801:Humans; D048031:JNK Mitogen-Activated Protein Kinases / Q000032:analysis; D027383:Papillomaviridae / Q000302:isolation & purification*; D011065:Poly(ADP-ribose) Polymerases / Q000032:analysis; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000032:analysis; D016159:Tumor Suppressor Protein p53 / Q000032:analysis; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000821:virology*
D000903:Antibiotics, Antineoplastic; D019253:Proto-Oncogene Proteins c-bcl-2; D016159:Tumor Suppressor Protein p53; D004317:Doxorubicin; D011065:Poly(ADP-ribose) Polymerases; D048031:JNK Mitogen-Activated Protein Kinases